• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Surmodics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    2/10/25 12:00:08 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email
    8-K
    0000924717false00009247172025-02-062025-02-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 06, 2025

     

     

    Surmodics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Minnesota

    0-23837

    41-1356149

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9924 West 74th Street

     

    Eden Prairie, Minnesota

     

    55344

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 952 500-7000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.05 par value

     

    SRDX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The Annual Meeting of Shareholders of Surmodics, Inc. (the “Company”) was held on February 6, 2025. The final voting results on the proposals, which were described in more detail in the Company’s proxy statement filed with the Securities and Exchange Commission on December 19, 2024, are set forth below.

    1.
    Election of Director. The individual nominated by the Company’s Board of Directors to serve as the Class II director was duly elected by the Company’s shareholders, and the final results of the votes cast are as follows:

     

     

    For

     

    Withheld

     

    Broker Non-Votes

    Gary R. Maharaj

     

    8,404,069

     

    187,820

     

    1,908,890

     

    2.
    Set the Number of Directors. The Company’s shareholders approved the proposal to set the number of directors at five (5) by the following vote:

    For

     

    Against

     

    Abstain

     

     

    10,441,062

     

    59,413

     

    304

     

     

     

    3.
    Ratification of the Appointment of Deloitte & Touche LLP. The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2025 by the following vote:

    For

     

    Against

     

    Abstain

     

     

    10,463,759

     

    35,348

     

    1,672

     

     

     

    4.
    Advisory Vote on Executive Compensation. The Company’s shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the following vote:

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    7,415,339

     

    1,043,557

     

    132,993

     

    1,908,890

     

    Item 9.01 Financial Statements and Exhibits.

    d) Exhibits.

    Exhibit

    Number

    Description

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SURMODICS, INC.

     

     

     

     

    Date:

    February 10, 2025

    By:

    /s/ Gordon S. Weber

     

     

     

    Senior Vice President of Legal, General Counsel and Secretary

     


    Get the next $SRDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/14/24 3:36:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/6/24 1:30:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      10/23/24 10:43:41 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/20/25 4:12:56 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:22:54 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:20:51 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SRDX
    Leadership Updates

    Live Leadership Updates

    See more

    $SRDX
    SEC Filings

    See more
    • Surmodics upgraded by Lake Street with a new price target

      Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

      3/7/25 8:21:43 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics upgraded by Needham with a new price target

      Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

      6/13/23 7:48:05 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics downgraded by Needham

      Needham downgraded Surmodics from Buy to Hold

      2/13/23 7:24:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

      European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the Eur

      4/22/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

      6/27/23 7:05:00 AM ET
      $KRMD
      $SRDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Surmodics Inc.

      SD - SURMODICS INC (0000924717) (Filer)

      5/20/25 5:30:03 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surmodics Inc.

      SCHEDULE 13G/A - SURMODICS INC (0000924717) (Subject)

      5/13/25 4:44:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Surmodics Inc.

      10-Q - SURMODICS INC (0000924717) (Filer)

      4/30/25 7:55:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Financials

    Live finance-specific insights

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

      1/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care